In a study presented at The Liver Meeting, researchers found that both FibroScan-aspartate aminotransferase (FAST) and Agile 3+ scores performed well in predicting the risk of advanced fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) who were treated with pegozafermin. The Agile 3+ score identified more patients at high risk for MASH compared to the FAST score. The study suggests that these noninvasive tests (NITs) could potentially replace biopsy for selecting patients for treatments like pegozafermin in the future. This is important because MASH is often underdiagnosed and undertreated, leading to potential complications like cirrhosis.
Source link
FAST, Agile 3+ scores may predict treatment benefit in MASH, advanced fibrosis
